ANALYST-UPGRADE filed
CICC initiates Pfizer (PFE) at Outperform with a $33 price target, implying 15.6% upside from the current $28.55. The move contrasts with a divided analyst base: 26 analysts show a mean PT of $28.58 and median of $27, with 37% Buy, 31% Hold, and 32% Sell ratings. CICC’s accuracy is 55% (17/31 calls correct), below top-tier firms like Morgan Stanley (71%, 5/7) and Cantor (59%, 10/17). Recent analyst activity includes one upgrade and no downgrades in 30 days. EPS estimates are trending down: -8bps in +1q EPS over 30 days. Institutional flows are mixed, Renaissance Technologies exited while Two Sigma increased position 27x. No insider trades or short interest data available. Earnings date not disclosed.